TVRD Tvardi Therapeutics Inc.
Price (delayed)
$18.85
Market cap
$86.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$15.53
Enterprise value
$92.76M
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in
Highlights
The quick ratio has surged by 162% year-on-year and by 139% since the previous quarter
Tvardi Therapeutics's EPS has increased by 41% YoY and by 26% from the previous quarter
Tvardi Therapeutics's equity has plunged by 108% YoY
The revenue has dropped by 66% year-on-year and by 18% since the previous quarter
Key stats
What are the main financial stats of TVRD
Market
Valuations
Earnings
Shares outstanding
4.57M
Market cap
$86.21M
Enterprise value
$92.76M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
12.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13
Revenue
$7.14M
Gross profit
$6.52M
Operating income
-$65.62M
Net income
-$70.87M
EBIT
-$62.79M
EBITDA
-$61.83M
Free cash flow
-$61.96M
Per share
Balance sheet
Liquidity
EPS
-$15.53
EPS diluted
-$15.53
Free cash flow per share
-$13.58
Book value per share
-$1
Revenue per share
$1.56
TBVPS
$9.61
Total assets
$43.83M
Total liabilities
$48.42M
Debt
$44.45M
Equity
-$4.59M
Working capital
$39.86M
Debt to equity
-9.68
Current ratio
11.03
Quick ratio
10.67
Net debt/EBITDA
-0.11
Margins
Efficiency
Dividend
EBITDA margin
-866.4%
Gross margin
91.3%
Net margin
-993%
Operating margin
-919.4%
Return on assets
-110%
Return on equity
-755.6%
Return on invested capital
-112.6%
Return on capital employed
-157.6%
Return on sales
-879.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TVRD stock price
How has the Tvardi Therapeutics stock price performed over time
Intraday
5.9%
1 week
10.63%
1 month
248.11%
1 year
124.4%
YTD
208.01%
QTD
271.79%
Financial performance
How have Tvardi Therapeutics's revenue and profit performed over time
Revenue
$7.14M
Gross profit
$6.52M
Operating income
-$65.62M
Net income
-$70.87M
Gross margin
91.3%
Net margin
-993%
TVRD's net margin has dropped by 76% year-on-year but it is up by 10% since the previous quarter
The revenue has dropped by 66% year-on-year and by 18% since the previous quarter
Tvardi Therapeutics's operating margin has plunged by 59% YoY but it has increased by 14% from the previous quarter
TVRD's gross profit has plunged by 56% YoY and by 13% from the previous quarter
Growth
What is Tvardi Therapeutics's growth rate over time
Valuation
What is Tvardi Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
12.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13
Tvardi Therapeutics's EPS has increased by 41% YoY and by 26% from the previous quarter
Tvardi Therapeutics's equity has plunged by 108% YoY
The revenue has dropped by 66% year-on-year and by 18% since the previous quarter
TVRD's P/S is 16% above its 5-year quarterly average of 10.4
Efficiency
How efficient is Tvardi Therapeutics business performance
Tvardi Therapeutics's return on equity has shrunk by 96% QoQ
Tvardi Therapeutics's ROS has plunged by 56% YoY but it has increased by 14% from the previous quarter
TVRD's return on invested capital is up by 36% year-on-year and by 15% since the previous quarter
TVRD's ROA is down by 23% YoY but it is up by 2.2% QoQ
Dividends
What is TVRD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TVRD.
Financial health
How did Tvardi Therapeutics financials performed over time
The total assets is 9% less than the total liabilities
The quick ratio has surged by 162% year-on-year and by 139% since the previous quarter
Tvardi Therapeutics's current ratio has soared by 143% YoY and by 131% from the previous quarter
The company's debt to equity has shrunk by 116% QoQ
Tvardi Therapeutics's equity has plunged by 108% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.